Recent research have focused on the overlap of glucagon-like peptide-1|GIP|GCGR activator therapies and dopaminergic neurotransmission. While GLP agonists are increasingly employed for treating type 2 diabetes https://henrixzpg772819.theideasblog.com/41893705/emerging-gip-agonists-and-da-modulation-a-contextual-assessment